ONCT Oncternal Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

ONCT [NASD]

Oncternal Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.24	Insider Own	5.70%	Shs Outstand	16.24M	Perf Week	-12.15%
Market Cap	37.34M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	103.60%	Shs Float	11.73M	Perf Month	-23.89%
Income	-19.30M	PEG	-	EPS next Q	-0.32	Inst Own	13.60%	Short Float	0.51%	Perf Quarter	-35.17%
Sales	2.50M	P/S	14.93	EPS this Y	-101.10%	Inst Trans	82.87%	Short Ratio	0.65	Perf Half Y	-27.97%
Book/sh	0.59	P/B	3.19	EPS next Y	28.60%	ROA	-92.60%	Target Price	-	Perf Year	-62.17%
Cash/sh	-	P/C	-	EPS next 5Y	0.00%	ROE	-147.30%	52W Range	1.82 - 6.29	Perf YTD	-52.41%
Dividend	-	P/FCF	-	EPS past 5Y	37.10%	ROI	-231.50%	52W High	-71.38%	Beta	0.92
Dividend %	-	Quick Ratio	2.00	Sales past 5Y	-	Gross Margin	-	52W Low	-1.30%	ATR	0.14
Employees	11	Current Ratio	2.00	Sales Q/Q	-14.30%	Oper. Margin	-	RSI (14)	21.59	Volatility	7.98% 6.26%
Optionable	No	Debt/Eq	0.03	EPS Q/Q	89.90%	Profit Margin	-	Rel Volume	1.08	Prev Close	1.88
Shortable	Yes	LT Debt/Eq	0.03	Earnings	Aug 06 AMC	Payout	-	Avg Volume	92.28K	Price	1.80
Recom	2.00	SMA20	-16.07%	SMA50	-28.21%	SMA200	-42.53%	Volume	62,138	Change	-4.26%

Sep-22-20 07:00AM	Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments PR Newswire
Sep-21-20 08:00AM	Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020 Business Wire
Sep-10-20 08:00AM	Oncternal Therapeutics to Participate in September Investor Conferences Business Wire
Sep-03-20 08:29AM	The Independent Director of Oncternal Therapeutics, Inc. (NASDAQ:ONCT), Michael Carter, Just Bought 13,789% More Shares Simply Wall St.
Aug-27-20 09:18PM	Oncternal Therapeutics Increases Previously Announced Bought Deal to $4.5 Million Business Wire
05:18PM	Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering Business Wire
Aug-06-20 04:15PM	Oncternal Provides Business Update and Announces Second Quarter 2020 Financial Results Business Wire
02:37PM	Oncternal Therapeutics'(NASDAQ:ONCT) Share Price Is Down 33% Over The Past Year. Simply Wall St.
Jul-30-20 08:00AM	Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update Business Wire -12.50%
Jul-27-20 08:00AM	Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma Business Wire
Jul-20-20 08:00AM	Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Business Wire
Jun-30-20 08:00AM	Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia Business Wire
07:45AM	Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma Business Wire
May-20-20 08:00AM	Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Business Wire
May-19-20 08:00AM	Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting Business Wire +23.17%
May-07-20 08:00AM	Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results Business Wire -5.87%
May-05-20 08:00AM	Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update Business Wire
May-01-20 08:00AM	Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update Business Wire
Mar-18-20 08:36AM	Is Oncternal Therapeutics (NASDAQ:ONCT) In A Good Position To Invest In Growth? Simply Wall St. -10.01%
Mar-16-20 04:05PM	Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results Business Wire
Mar-11-20 04:08PM	Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update Business Wire +12.20%
08:00AM	Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma Business Wire
Feb-06-20 08:00AM	Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Business Wire
Dec-12-19 06:00PM	Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium Business Wire
Dec-11-19 08:00AM	Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma Business Wire -10.62%
Dec-09-19 08:00AM	Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting Business Wire
Dec-03-19 08:00AM	Oncternal Therapeutics to Present Cirmtuzumab Clinical Data Updates at 2019 ASH Annual Meeting and San Antonio Breast Cancer Symposium Business Wire
Nov-21-19 08:00AM	Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference Business Wire
Nov-14-19 04:02PM	Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting Business Wire
Nov-11-19 08:00AM	Oncternal Therapeutics to Present at Stifel Healthcare Conference Business Wire +5.74%
Nov-07-19 04:05PM	Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Nov-05-19 08:00AM	Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting Business Wire +8.80%
Oct-31-19 08:00AM	Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update Business Wire
Oct-03-19 08:00AM	Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma Business Wire
Sep-20-19 12:03PM	We're Not Very Worried About Oncternal Therapeutics's (NASDAQ:ONCT) Cash Burn Rate Simply Wall St.
Sep-17-19 04:05PM	Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Childrens Oncology Group Meeting Business Wire -5.70%
Sep-09-19 08:00AM	Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer Business Wire
Aug-28-19 04:01PM	Oncternal Expands Leadership Team with Appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior VP CMC and Manufacturing Business Wire
Aug-08-19 04:01PM	Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Aug-06-19 08:00AM	Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib GlobeNewswire +5.75%
Aug-01-19 04:01PM	Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update GlobeNewswire -5.29%
Jun-10-19 08:00AM	Oncternal Therapeutics Completes Reverse Merger with GTx, Inc. GlobeNewswire -16.31%

Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer. It is also developing a chimeric antigen receptor-T product candidate that targets ROR1, which is currently in preclinical development for treating hematologic cancers and solid tumors. The company is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CARTER MICHAEL G	Director	Sep 01	Buy	2.10	71,429	150,001	71,947	Sep 02 04:53 PM
AKER HAZEL M	Legal Counsel	Jul 21	Buy	2.38	41,972	99,998	46,987	Jul 23 05:00 PM
KISNER DANIEL L	Director	Jul 21	Buy	2.38	10,000	23,825	10,000	Jul 23 05:00 PM
Shanghai Pharmaceutical (USA)	10% Owner	Jul 21	Buy	2.38	1,049,317	2,499,998	3,544,431	Jul 23 04:32 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience